These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 283838)

  • 1. Multiple determinants of antimetabolite action in humans.
    Rustum YM
    Bull Cancer; 1979; 66(1):93-6. PubMed ID: 283838
    [No Abstract]   [Full Text] [Related]  

  • 2. Rationales for a pharmacologically optimized treatment of acute nonlymphocytic leukemia with cytosine arabinoside.
    Heinemann V; Jehn U
    Leukemia; 1990 Nov; 4(11):790-6. PubMed ID: 2232893
    [No Abstract]   [Full Text] [Related]  

  • 3. Accumulation of arabinosyluracil 5'-triphosphate during arabinosylcytosine therapy in circulating blasts of patients with acute myelogenous leukemia.
    Gandhi V; Xu YZ; Estey E
    Clin Cancer Res; 1998 Jul; 4(7):1719-26. PubMed ID: 9676847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and cellular determinants of response to 1-beta-arabinofuranosylcytosine (ara-C).
    Riva CM; Rustum YM; Preisler HD
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):1-8. PubMed ID: 3859925
    [No Abstract]   [Full Text] [Related]  

  • 5. Cytosine arabinoside deamination in human leukaemic myeloblasts and resistance to cytosine arabinoside therapy.
    Harris AL; Grahame-Smith DG; Potter CG; Bunch C
    Clin Sci (Lond); 1981 Feb; 60(2):191-8. PubMed ID: 6940687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation between leukemic cell retention of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate and response to therapy.
    Rustum YM; Preisler HD
    Cancer Res; 1979 Jan; 39(1):42-9. PubMed ID: 282940
    [No Abstract]   [Full Text] [Related]  

  • 7. Cellular pharmacology and optimal therapeutic concentrations of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in leukemic blasts during treatment of refractory leukemia with high-dose 1-beta-D-arabinofuranosylcytosine.
    Plunkett W; Iacoboni S; Keating MJ
    Scand J Haematol Suppl; 1986; 44():51-9. PubMed ID: 3457439
    [No Abstract]   [Full Text] [Related]  

  • 8. Relapse of acute myeloid leukemia as isolated bilateral testicular granulocytic sarcoma in an adult.
    Ghadiany M; Attarian H; Hajifathali A; Khosravi A; Molanaee S
    Urol J; 2008; 5(2):132-4; discussion 134-5. PubMed ID: 18592470
    [No Abstract]   [Full Text] [Related]  

  • 9. Degradation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in human leukemic myeloblasts and lymphoblasts.
    Jamieson GP; Finch LR; Snook M; Wiley JS
    Cancer Res; 1987 Jun; 47(12):3130-5. PubMed ID: 3472653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of acute myeloid leukemia].
    Obrecht JP
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1984; 111(2):190-200. PubMed ID: 6208102
    [No Abstract]   [Full Text] [Related]  

  • 11. Intracellular cytarabine triphosphate production correlates to deoxycytidine kinase/cytosolic 5'-nucleotidase II expression ratio in primary acute myeloid leukemia cells.
    Yamauchi T; Negoro E; Kishi S; Takagi K; Yoshida A; Urasaki Y; Iwasaki H; Ueda T
    Biochem Pharmacol; 2009 Jun; 77(12):1780-6. PubMed ID: 19428333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of therapeutic response in acute myelocytic leukemia.
    Preisler HD; Rustum YM
    Haematol Blood Transfus; 1979; 23():93-8. PubMed ID: 296118
    [No Abstract]   [Full Text] [Related]  

  • 13. Biochemical and cellular pharmacology of cytosine arabinoside.
    Kufe DW; Spriggs DR
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):34-48. PubMed ID: 3925560
    [No Abstract]   [Full Text] [Related]  

  • 14. Sequential high-dose ara-C and asparaginase in the therapy of previously treated and untreated patients with acute leukemia.
    Capizzi RL; Powell BL; Cooper MR; Stuart JJ; Muss HB; Richards F; Jackson DV; White DR; Spurr CL; Zekan PJ
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):105-13. PubMed ID: 3892697
    [No Abstract]   [Full Text] [Related]  

  • 15. Quantitation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in the leukemic cells from bone marrow and peripheral blood of patients receiving 1-beta-D-arabinofuranosylcytosine therapy.
    Plunkett W; Hug V; Keating MJ; Chubb S
    Cancer Res; 1980 Mar; 40(3):588-91. PubMed ID: 6937239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An unusual initial manifestation of acute leukemia.
    Desai A; Desai A; Staszewski H; Cunha BA
    Am J Med; 2012 Dec; 125(12):1173-4. PubMed ID: 23062401
    [No Abstract]   [Full Text] [Related]  

  • 17. [Therapy of acute leukemia. Opinion of Prof. Franco Mandelli].
    Salvati A
    Minerva Med; 1973 Jan; 64(4):170-2. PubMed ID: 4510268
    [No Abstract]   [Full Text] [Related]  

  • 18. Effective clearance of Ara-U the major metabolite of cytosine arabinoside (Ara-C) by hemodialysis in a patient with lymphoma and end-stage renal failure.
    Radeski D; Cull GM; Cain M; Hackett LP; Ilett KF
    Cancer Chemother Pharmacol; 2011 Apr; 67(4):765-8. PubMed ID: 20532508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacologic studies of low-dose and high-dose continuous infusion cytosine arabinoside.
    Kufe DW; Spriggs DR; Griffin JD
    Semin Oncol; 1987 Jun; 14(2 Suppl 1):149-58. PubMed ID: 3473675
    [No Abstract]   [Full Text] [Related]  

  • 20. A microarray study of altered gene expression after cytarabine resistance in acute myeloid leukemia.
    Yin B; Tsai ML; Hasz DE; Rathe SK; Le Beau MM; Largaespada DA
    Leukemia; 2007 May; 21(5):1093-7. PubMed ID: 17301810
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.